NAD + vs NMN: Dab tsi NAD Booster zoo dua rau kev noj zaub mov ntxiv?

Rau cov pab pawg tsim B2B thiab cov thawj coj saib xyuas kev tsim kho tom ntej -cov khoom lag luam ua haujlwm ntev, cov lus nug uas tshwm sim yog seb puas tsim nrog cov coenzyme nquagNAD ⁺los yog nws tus thawj coj ncaj qha NMN. Txawm hais tias ob qho tib si molecules yog lub hauv paus rau NAD⁺ kev sib tham hauv cov metabolism, lawv ua haujlwm sib txawv hauv cov cellular biology- thiab qhov sib txawv no muaj qhov cuam tshuam ncaj qha rau kev tsim cov tswv yim, bioavailability, thiab cov khoom tiav.

NAD⁺ (nicotinamide adenine dinucleotide) yog cov nquag coenzyme uas cov hlwb siv rau lub zog metabolism, kho DNA, thiab ua kom sirtuin. NMN (nicotinamide mononucleotide) yog lub hauv paus molecule uas lub cev hloov mus rau hauv NAD⁺. Cov lus nug tseem ceeb rau B2B cov neeg yuav khoom tsis yog qhov twg molecule yog "zoo dua," tab sis cov khoom xyaw twg yog qhov siv tau ntau dua thiab raug nqi - zoo rau qhov ncauj ntxiv.

 

 

 

• NAD⁺ yog lub active coenzyme; NMN yog qhov ua ntej uas lub cev hloov mus rau NAD⁺.
• Qhov ncauj tswj hwm NAD⁺ yog degraded sai heev los ntawm extracellular enzymes ua ntej cov hnyuv nqus tau zoo tuaj yeem tshwm sim, ua cov ntaub ntawv precursor zoo dua rau qhov ncauj supplementation.
• NMN tau pom nyob rau hauv ntau qhov kev sim tib neeg kom muaj kev nyab xeeb thiab ua tau zoo nce ntshav NAD⁺ qib.
• Liposomal NMN formulations yog tsim los txhim kho cov khoom ruaj khov thiab tuaj yeem txhim kho qhov ncauj bioavailability piv nrog cov qauv NMN, txawm hais tias tseem xav tau kev kuaj mob ntxiv.
• Los ntawm qhov kev xav ntawm kev yuav khoom, NMN yog qhov kev xaiv zoo rau cov qauv ntawm qhov ncauj; direct NAD⁺ yog qhov zoo dua rau cov kab mob hauv cov hlab ntsha lossis kev xa khoom tshwj xeeb. Raubulk NMN hmoovkev nrhiav, pab pawg yuav khoom yuav tsum tau ua ntej rau cov neeg xa khoom nrog cov ntaub ntawv txheeb xyuas cov ntaub ntawv pov thawj thiab cov khoom sib xws - rau - cov khoom sib xws.

 

 

NAD⁺ yog ib qho coenzyme pom nyob rau hauv txhua lub cell nyob, qhov tseem ceeb rau kev hloov cov as-ham rau hauv lub zog, tswj cov txheej txheem ntawm tes, thiab ua kom cov proteins koom nrog hauv DNA kho thiab kev ntxhov siab. Raws li peb muaj hnub nyoog, NAD⁺ qib ib txwm poob qis, ua rau txo qis cellular efficiency thiab hnub nyoog- cuam tshuam txog kev noj qab haus huv.

NMN yog bioactive nucleotide muab tau los ntawm vitamin B3 uas tshwm sim nyob rau hauv lub cev thiab muaj nyob rau hauv me me nyob rau hauv cov khoom noj xws li zaub qhwv, edamame, thiab avocados. NMN yog ib qho tseem ceeb nruab nrab ntawm biosynthesis ntawm NAD⁺. Qhov sib txawv tseem ceeb: NAD⁺ yog lub zog molecule koj lub hlwb siv; NMN yog cov khoom siv raw koj lub cev hloov mus rau NAD⁺.

Qhov no yog vim li cas ncaj qha NAD⁺ supplementation ntsib ib qho kev sib tw tseem ceeb: extracellular NAD⁺ yog sai sai degraded los ntawm ectoenzymes xws li CD38, ENPP1, thiab CD73 ua ntej cov hnyuv nqus tau zoo tuaj yeem tshwm sim. Qhov kev pom zoo ntawm kev tshawb fawb taw qhia rau lwm txoj hauv kev- siv cov khoom ua ntej uas cov hlwb tuaj yeem nqus tau thiab hloov pauv.

Qhov no txhais tau li cas rau kev yuav khoom: Direct NAD⁺ yog qhov siv tsis tau rau cov qauv ntawm qhov ncauj. NMN yog qhov kev xaiv ua tau zoo rau cov khoom noj hauv qhov ncauj tsim los txhawb nqa qib NAD⁺. Rau hom nrhiav aLiposomal NMN chaw tsim tshuaj paustus khub, kev ntsuam xyuas encapsulation technology thiab stability cov ntaub ntawv yog qhov tseem ceeb.

 

 

Ob leeg NAD⁺ thiab NMN ua haujlwm nyob rau hauv NAD⁺ txoj kev khaws cia, tab sis lawv nkag mus rau txoj hauv kev no ntawm cov ntsiab lus sib txawv- qhov txawv nrog cuam tshuam rau kev ua haujlwm metabolic thiab ua tau zoo.

NAD⁺ yog qhov kawg ntawm txoj kev. Nws tau noj los ntawm cov enzymes xws li sirtuins, PARPs, thiab CD38 thaum lub sij hawm cellular txheej txheem, ces tawg mus rau hauv nicotinamide (NAM), uas yog recycled rov qab rau hauv NAD⁺ ntawm txoj kev khaws cia. Ntxiv nrog rau NAD⁺ ncaj qha yuav theoretically bypass cov txheej txheem ub no, tab sis cov molecule lub extracellular degradation thiab tsis zoo ntawm qhov ncauj bioavailability ua rau txoj kev no tsis zoo.

NMN nkag mus rau txoj kev cawm seej ib kauj ruam ua ntej NAD⁺. Nws hloov mus rau NAD⁺ hauv ib kauj ruam enzymatic los ntawm Nicotinamide Mononucleotide Adenylyltransferase (NMNAT). Qee qhov kev tshawb fawb tau qhia tias Slc12a8 tuaj yeem koom nrog NMN thauj hauv cov ntaub so ntswg tshwj xeeb, txawm hais tias nws lub luag haujlwm ntawm lub cev tseem nyob hauv kev tshawb nrhiav.

Ib txoj kev tshawb fawb 2026 luam tawm hauvNtuj Metabolismpiv peb NAD⁺ boosters-NAM, NR, thiab NMN- hauv 65 tus neeg koom nrog noj qab haus huv tshaj 14 hnub. Txoj kev tshawb nrhiav pom tias ob qho tib si NR thiab NMN piv rau cov hlab ntsha NAD⁺ ntau dua hauv cov neeg laus noj qab haus huv, thaum NAM tsis ua. Txoj kev tshawb no qhia tias lub plab - txoj hauv kev ua haujlwm metabolic ua rau nce siab ntawm NAD⁺ tom qab NR thiab NMN supplementation. Qhov kev tshawb pom no ntxiv txhawb nqa kev siv NMN los ua pov thawj-raws li NAD⁺ tus thawj coj rau kev tsim kho qhov ncauj.

Qhov no txhais li cas rau formulators:NMN yog qhov zoo -tus yam ntxwv NAD⁺ ua ntej nrog cov ntaub ntawv pov thawj ntawm kev ua tau zoo ntawm tib neeg. NAD⁺, thaum ua haujlwm lom neeg, tsis haum rau kev xa tawm qhov ncauj.

 

 

Bioavailability yog qhov sib txawv tseem ceeb ntawm ob cov khoom xyaw no- thiab qhov laj thawj tseem ceeb NMN tau dhau los ua qhov kev xaiv zoo tshaj plaws rau kev tsim ntawm qhov ncauj.

Oral NAD ⁺nthuav tawm txoj hnyuv bioavailability tsis zoo vim yog degradation sai los ntawm cov enzymes extracellular. Extracellular NAD⁺ tau tawg los ntawm ectoenzymes xws li CD38, ENPP1, thiab CD73 ua ntej nws tuaj yeem nqus tau zoo. Feem ntau ntawm qhov ncauj NAD⁺ yog degraded ua ntej nws tuaj yeem ncav cuag cov kab mob hauv lub cev, ua rau nws tsis muaj txiaj ntsig rau kev nce qib ntawm cellular NAD⁺. Direct NAD⁺ supplementation feem ntau txwv rau kev tswj cov hlab ntsha.

Standard NMNtau nqus los ntawm qhov ncauj thiab tau pom nyob rau hauv ntau qhov kev tshawb fawb tib neeg kom nce ntshav NAD⁺ qib. A 2026Ntuj Metabolismtxoj kev tshawb fawb pom tau tias 14 hnub ntawm NMN supplementation piv rau circulatory NAD⁺ concentrations nyob rau hauv cov neeg laus noj qab nyob zoo. Ib lub lim tiam 12-randomized, ob npaug- dig muag, placebo- tswj kev sim hauv 36 cov neeg laus hnub nyoog noj qab haus huv tau pom tias kev noj NMN txhua hnub (250 mg) muaj kev nyab xeeb, tsis muaj qhov cuam tshuam tsis zoo.

Liposomal NMNsawv cev rau txoj kev xa khoom siab heev. Los ntawm encapsulating NMN nyob rau hauv phospholipid bilayers, liposomal formulations tiv thaiv NMN los ntawm degradation thiab yuav pab txhawb cellular uptake. RauOEM NMNcov neeg koom tes, ntsuas liposomal encapsulation tshuab thiab cov ntaub ntawv ruaj khov yog qhov tseem ceeb los xyuas kom meej cov khoom tiav tiav.

Qhov no txhais tau li cas rau kev yuav khoom:Standard NMN muaj qhov ua tau zoo, pov thawj- txhawb nqa mus rau NAD⁺ nce. Liposomal NMN muaj peev xwm nqus tau zoo, txawm tias tus nqi siab dua. Direct NAD⁺ tsis yog ib qho kev xaiv siv tau rau qhov ncauj tshuaj.

 

 

NMN tau kawm hauv ntau qhov kev sim tshuaj tib neeg, nrog lub cev loj hlob ntawm cov pov thawj txhawb nqa nws txoj kev nyab xeeb thiab kev ua tau zoo.

NMN human trials:

• A 2026 Ntuj Metabolismtxoj kev tshawb fawb (65 tus neeg koom nrog noj qab haus huv, 14 hnub) pom tias NMN sib piv nce circulatory NAD⁺ concentrations.
• Ib qho 12-lub lim tiam randomized, ob npaug - dig muag, cov placebo- tswj kev sim hauv 36 cov neeg laus hnub nyoog noj qab haus huv tau pom tias kev noj NMN txhua hnub (250 mg) muaj kev nyab xeeb, tsis muaj kev cuam tshuam tsis zoo.
• Kev qhib me me -label kuaj sim hauv 11 tus neeg noj qab haus huv nruab nrab- cov txiv neej Nyij Pooj hnub nyoog (125 mg NMN ob zaug ib hnub) pom tias NMN tau zoo- zam thiab ua tau zoo txhawb NAD⁺ biosynthesis.
• Ib 12-lub lim tiam ob- qhov muag tsis pom kev, randomized, kev tswj cov placebo hauv cov neeg laus pom tias NMN noj cov ntshav nce NAD⁺ qib, tswj kev taug kev nrawm, thiab txhim kho kev pw tsaug zog zoo.

NAD⁺ human pov thawj:

• Direct NAD⁺ supplementation tau txwv tib neeg cov pov thawj vim qhov ncauj tsis zoo bioavailability.
• Feem ntau cov kev tshawb fawb ntawm NAD⁺ cuam tshuam nrog txoj kev xa hauv cov hlab ntsha los yog intranasal.

Qhov no txhais tau li cas rau kev yuav khoom:NMN muaj lub cev muaj zog thiab loj hlob ntawm tib neeg cov pov thawj kho mob txhawb nqa nws txoj kev nyab xeeb thiab ua tau zoo. Direct NAD⁺ tau txwv cov ntaub ntawv ntawm qhov ncauj bioavailability thiab feem ntau yog siv rau hauv cov chaw tso dej.

 

 

Los ntawm qhov kev xav ntawm kev yuav khoom, tus nqi yog qhov tseem ceeb rau kev txiav txim siab. Txawm li cas los xij, kev txheeb xyuas tus nqi yuav tsum suav rau ob qho tib si raw khoom pricing thiab siv tau zoo.

NAD⁺ feem ntau tsis yog ib qho kev xaiv siv tau rau cov qauv hauv qhov ncauj, yog li kev sib piv tus nqi feem ntau cuam tshuam rau cov ntawv thov hauv cov hlab ntsha.

NMN raw khoom tus nqi sib txawv raws li purity, tsum, thiab txiav txim ntim. Siab -purity NMN hmoov (Ntau dua lossis sib npaug li 98% lossis siab dua) hais kom tus nqi them vim qhov nyuaj ntawm cov txheej txheem tsim khoom. Ob leeg NMN thiab NR yog tsim NAD⁺ precursors nrog txawv metabolic pathways thiab loj hlob cov ntaub ntawv soj ntsuam.

Liposomal NMN ntxiv cov nqi tsim khoom ntxiv vim yog phospholipid raw cov ntaub ntawv, homogenization, thiab particle- tswj qhov loj, tab sis tuaj yeem tso cai qis qis dua vim kev nqus tau zoo dua.

Lwm qhov kev txiav txim siab txog kev yuav khoom muaj xws li kev tswj hwm txoj cai, kev ua raws hauv cheeb tsam, kev ruaj ntseg ntawm cov khoom siv, patent toj roob hauv pes, thiab lub peev xwm tsim khoom.

Qhov no txhais tau li cas rau kev yuav khoom:NMN yog qhov kev xaiv ua tau zoo rau qhov ncauj NAD⁺- txhawb nqa cov qauv. Tus nqi them nqi rau liposomal NMN yuav tsum raug soj ntsuam los ntawm cov txiaj ntsig kev noj qab haus huv ntau npaum li cas.

 

 

Qhov xwm txheej	NAD ⁺	NMN (Standard)	NMN (Liposomal)
Biological luag hauj lwm	Active coenzyme	Direct precursor	Direct precursor
Qhov ncauj bioavailability	pluag heev (degraded los ntawm ectoenzymes)	Nruab nrab	Txhim kho
Cov pov thawj kho mob	Txwv (qhov ncauj); IV pov thawj muaj	Lub cev loj hlob ntawm tib neeg kev sim siab	Cov ntaub ntawv kho mob tshiab
Formulation practicality	Tsis haum rau qhov ncauj	Haum rau cov tshuaj ntsiav, ntsiav tshuaj, hmoov	Haum rau cov txheej txheem siab heev
Nqi (ib koob tshuaj zoo)	Tsis siv tau	Nruab nrab	Siab dua
Pov thawj muaj zog	Txwv tsis pub	Loj hlob	Tawm tshiab
Zoo tshaj plaws rau	IV/clinical settings	Cov khoom noj hauv qhov ncauj, tus nqi - cov kab rhiab heev	Hwm, kev tshawb fawb- cov khoom muag

 

 

 

Puas yog NAD⁺ zoo dua NMN?
NAD⁺ yog cov nquag coenzyme uas cov hlwb siv, tab sis nws qhov tsis zoo ntawm qhov ncauj bioavailability ua rau nws tsis haum rau cov qauv tshuaj ntxiv. NMN tau pom nyob rau hauv ntau qhov kev tshawb fawb soj ntsuam kom nce qib NAD⁺ tom qab noj tshuaj ntxiv.

NAD⁺ puas tuaj yeem nqus tau qhov ncauj?
Qhov ncauj noj NAD⁺ yog degraded sai heev los ntawm extracellular enzymes ua ntej cov hnyuv nqus tau zoo tuaj yeem tshwm sim. Qhov no yog vim li cas cov ntaub ntawv precursor xws li NMN yog qhov ua tau zoo dua rau kev ntxiv qhov ncauj.

Puas yog liposomal NMN zoo dua?
Cov kev tshawb fawb thaum ntxov qhia tias liposomal NMN tuaj yeem txhim kho qhov cuam tshuam nrog rau cov qauv NMN, txawm hais tias xav tau kev sim tshuaj ntsuam xyuas ntxiv.

Dab tsi purity yuav tsum tau thov?
Pab pawg neeg yuav khoom yuav tsum thov NMN nrog Ntau dua lossis sib npaug li 98% purity txheeb xyuas los ntawm HPLC, nrog rau kev tshuaj xyuas cov hlau hnyav, cov ntaub ntawv kev nyab xeeb microbiological, thiab batch- Cov Ntawv Pov Thawj Tshwj Xeeb ntawm Kev Ntsuam Xyuas.

Cov neeg tsim khoom yuav tsum xaiv li cas ntawm NMN thiab NR?
Ob leeg NMN thiab NR yog tsim NAD⁺ precursors nrog txawv metabolic pathways thiab loj hlob cov ntaub ntawv soj ntsuam. Qhov kev xaiv yog nyob ntawm cov hom phiaj tsim, kev txiav txim siab nqi, thiab lub hom phiaj kev lag luam. Raubulk NAD precursorKev tsim khoom, ntsuas cov peev txheej ntawm cov khoom lag luam thiab cov ntaub ntawv tswj hwm yog qhov tseem ceeb.

 

 

Rau kev noj zaub mov ntawm qhov ncauj, pov thawj kev kho mob tam sim no qhia tias NMN yog qhov ua tau zoo tshaj NAD⁺ precursor rau qhov ncauj supplementation vim tias nws tuaj yeem hloov mus rau hauv NAD⁺ tom qab nqus tau zoo, qhov kev siv qhov ncauj ntawm NAD⁺ yog degraded ntau dua ua ntej mus txog qhov systemic circulation. NMN tau qhia txog kev nyab xeeb thiab kev ua tau zoo hauv ntau qhov kev sim tshuaj tib neeg, suav nrog randomized, ob npaug - dig muag, placebo- tswj kev tshawb fawb. Liposomal NMN tuaj yeem txhim kho kev xa khoom kom zoo rau cov qauv tsim nyog, txawm hais tias ntxiv loj - cov kev tshawb fawb soj ntsuam tseem tau lees paub.

 

 

Rau B2B cov thawj coj kev yuav khoom thiab cov neeg tsim khoom, kev xaiv ntawm NAD⁺ thiab NMN tsis yog lo lus nug ntawm qhov twg molecule muaj zog dua - nws yog ib lo lus nug ntawm cov khoom xyaw twg yog qhov siv tau, tus nqi - zoo, thiab kev txhawb nqa los ntawm cov pov thawj rau qhov ncauj ntxiv. NAD⁺ yog cov nquag coenzyme uas cov hlwb siv, tab sis nws cov degradation sai heev los ntawm extracellular enzymes ua rau nws tsis tsim nyog rau cov qauv ntxiv formulations. NMN yog tus thawj coj ncaj qha rau NAD⁺, nrog lub cev loj hlob ntawm tib neeg cov pov thawj kho mob, suav nrog 2026Ntuj Metabolismkawm, txhawb nws txoj kev nyab xeeb thiab kev ua tau zoo hauv kev nce ntshav NAD⁺ qib. Rau cov khoom lag luam tsom mus rau kev ua lag luam kev noj qab haus huv zoo tshaj plaws, liposomal NMN muaj peev xwm txhim kho bioavailability ntawm tus nqi siab dua. Los ntawm kev koom tes nrog tus neeg muab khoom lag luam pob tshab uas muab cov ntaub ntawv txheeb xyuas tau tseeb, cov ntaub ntawv ruaj khov, thiab cov ntawv pov thawj tshwj xeeb, cov tuam txhab tuaj yeem xaiv qhov tsim nyog tshaj plaws NAD⁺ precursor lub tswv yim raws li lawv lub hom phiaj kev lag luam, tsim cov hom phiaj, thiab cov kev cai tswj hwm.

 

Cov kauj ruam tom ntej rau koj cov qauv

Feem ntau cov neeg siv khoom pib nrog kev tsav tsheb batch (100-500 g) kom siv tau cov dispersibility, stability, thiab formulation kev ua tau zoo nyob rau hauv lawv cov matrix tshwj xeeb ua ntej scaling rau kev lag luam ntau lawm. Batch-specific COA, cov ntaub ntawv loj me me, thiab kev tshawb fawb ruaj khov muaj los txhawb koj cov txheej txheem tsim khoom.

• [Thov ntau NMN hmoov cov qauv & Cov ntaub ntawv Technical]- Ntsuam xyuas peb cov qib NMN hmoov (Ntau dua lossis sib npaug rau 98% purity) lossis liposomal NMN formulations hauv koj tus kheej matrix.
• [Access technical documentation]- Txheeb xyuas HPLC cov ntaub ntawv ntsuam xyuas, particle loj faib (DLS), hnyav hlau tsom xam, thiab kev tshawb fawb ruaj khov.
• [ Sib tham txog kev cai specifications]- Tshawb nrhiav kev cai ntau, kev xaiv liposomal encapsulation, lossis kev txhawb nqa kev tsim.
• [Schedule ib tug formulation kev sab laj]- Ntsib nrog peb pab neeg R&D los hais txog NAD⁺ lub tswv yim ua ntej, bioavailability, lossis daim ntawv thov - cov kev cov nyom tshwj xeeb.

MOQ, lub sijhawm ua haujlwm, thiab tus nqi ntau yog muaj thaum thov. Wellgreen muab batch- tshwj xeeb COA, particle- tsom xam qhov loj me, kev txhawb nqa tsim, thiab OEM / ODM cov kev pabcuam rau cov tuam txhab nutraceutical thoob ntiaj teb. Rau kev txhawb nqa, kev sib tham txog kev tsim, thiab cov lus hais ntau, hu rau peb pawg neeg ua haujlwm engineering ntawmliu@wellgreenxa.com.

 

Cov ntaub ntawv

1. Qhov sib txawv ntawm peb qhov sib txawv NAD + boosters ntawm circulatory NAD thiab microbial metabolism hauv tib neeg.Ntuj Metabolism, 2026, 8, 62-73. PIB: 10.1038/s42255-025-01421-8. ClinicalTrials.gov: NCT05517122.
2. Kev nyab xeeb thiab kev ua tau zoo ntawm ntev -lub sij hawm nicotinamide mononucleotide supplementation ntawm metabolism, pw tsaug zog, thiab NAD + biosynthesis nyob rau hauv noj qab haus huv, nruab nrab- cov txiv neej Nyiv.CiNii Research, 2025. Qhib-label kuaj sim (11 tus neeg koom, 125 mg NMN ob zaug ib hnub).
3. Kev noj haus ntawm -nicotinamide mononucleotide nce ntshav NAD qib, tswj kev taug kev nrawm, thiab txhim kho kev pw tsaug zog zoo hauv cov neeg laus.GeroScience, 2024. 12-lub lim tiam ob - dig muag, randomized, placebo- tswj kev kawm.
4. Ib 12-lub limtiam randomized, ob npaug- dig muag, placebo- tswj kev sim hauv 36 tus neeg laus noj qab haus huv: NMN txhua hnub (250 mg) muaj kev nyab xeeb, tsis muaj teebmeem dabtsi.J-STAGE, 2026.
5. Grozio, A., et al. (2019). Slc12a8 yog nicotinamide mononucleotide transporter.Ntuj Metabolism, 1, 47–57.
6. Schmidt, MS, & Brenner, C. (2019). Tsis muaj pov thawj tias Slc12a8 encodes nicotinamide mononucleotide transporter.Ntuj Metabolism, 1, 660-661.
7. Extracellular metabolism ntawm -nicotinamide adenine dinucleotide ( -NAD) nyob rau hauv murine nyuv.PubMed. CD38 mediated conversion of eNAD to eADPR; ENPP1 kev sib haum xeeb degradation ntawm eNAD thiab eADPR rau eAMP.